Diabetes

On March 8, the FDA approved the injectable weight loss medication, semaglutide, for reducing the risk of cardiovascular events such as heart attack, stroke, and cardiovascular death in adults with heart...

Researchers examined the accuracy and viability of automated machine learning models for identifying diabetic retinopathy progression from the use of ultra-widefield retinal images.

This COVID-19 roundup includes coverage of the FDA’s guidance for the correct Moderna vaccine dosage for pediatric patients, COVID-19 outcomes for patients with hypertension and diabetes, and the risk of...

In this Roundtable Wrap-Up, we offer an abbreviated version of the roundtable discussion on the multidisciplinary approach to managing people with diabetes, the importance of diabetes self-care and...

Researchers compared the effects of once-weekly semaglutide (2.4 mg) with a placebo during a 52-week period in patients with HFpEF and a BMI of 30 or higher.

Tirzepatide is now approved for a new indication. The dual GIP/GLP-1 agonist was previously approved for treating type 2 diabetes in May 2022.

This COVID-19 roundup includes coverage of the combination of amubarvimab and romlusevimab to manage COVID-19 infection, the association between COVID-19 and incident diabetes, and the effectiveness of...

This COVID-19 roundup includes coverage of the FDA’s amendment to its emergency use authorization of the Pfizer-BioNTech booster for pediatric patients, acute myocardial infection deaths rose during omicron...